Merck & Company MRK

$145.60 +3.22 (2.26%)

Valuation

Market cap
351,275,968,000
Revenue TTM
$65,011,000,000
Net income TTM
$18,254,000,000
PE ratio
44.48
Forward PE
53.42
Profit margin
28.08%
Debt to equity
1.22

Trading

Volume
9,288,700
Avg volume
10,137,750
Day's range
$141.36 – $146.68
Shares out
2,467,172,000
Stochastic %K
59%
Beta
0.21
Analysts
Strong Sell
Price target
$159.04

Price

Company profile

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. Th...

Show more

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
908 740 4000
Website
https://www.merck.com
Address
126 East Lincoln Avenue, Rahway, United States

Latest news

Stocktwits

Kawasaki1 Oct 10, 5:10 AM
$NVAX Is it Monday yet? $QQQ $SPY $MRK
0 replies
taxplanr Oct 10, 2:47 AM
Breaking News from Russia on the plague 🤣🤣🤣$MRNA $MRK $BNTX https://www.instagram.com/reel/DeOl90FKBuO/?exln=MWE2bWVlNnJ3dDJobw==
0 replies
GlassIsHalfEmpty Oct 10, 1:50 AM
$IBRX Some of the rally today in $XBI can be because of the nih gov sponsored cancer vax program that is set to kickoff this Dec. Besides $MRK $MRNA $BNTX Ibrx also is in the race, hopefully not another op warp speed fiasco! • Tri-Ad5 Cancer Vaccines: Tri-Ad5 targeting CEA, MUC1, and brachyury). • Lynch Syndrome Trial: a randomized controlled trial sponsored by the National Cancer Institute (NCI/NIH) testing its Tri-Ad5 vaccine combined with its IL-15 superagonist (ANKTIVA) in patients with Lynch syndrome. • Phase 1 trials for therapeutic candidates like IBRX-042 targeting HPV-associated tumors (such as cervical, head and neck, and anal carcinomas). • Unlike traditional mRNA based vaccines (like Merck and Moderna's intismeran autogene or BioNTech's), Ibrx’s broader approach centers on its Cancer BioShield platform , combining adenovirus vaccines w NK cell therapies with fda approved ANKTIVA https://finance.yahoo.com/healthcare/articles/bntx-nvax-mrna-lead-vaccine-000924071.html
1 replies
JeffFaffa Oct 10, 12:55 AM
$MRNA $SLS $MRKR Wouldn't it be funny if a junior buyer loads up on $MRKR instead of $MRK only for his boss to scream "bloody hell...u asshole! how do u mix these up? one is a multi billion company run by actual people while the other is a penny stock run by a donkey!" 😂
2 replies
StocktwitsNews Oct 10, 12:09 AM
BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push $NVAX $MRNA $PFE $BNTX $MRK https://stocktwits.com/news/equity/markets/bntx-nvax-mrna-lead-vaccine-rally-after-report-of-an-nih-cancer-vaccine-push/cZxTXZZRBnm
0 replies
BrianPia Oct 9, 9:18 PM
$MRNA surged 14% Friday to a new 52-week high, and the NIH’s planned cancer-vaccine initiative may be the biggest catalyst. The National Institutes of Health and the Foundation for the NIH are assembling a public-private partnership, expected to launch in December, to accelerate personalized cancer vaccines. Initial targets include pancreatic, liver and colorectal cancers and certain pediatric tumors. These vaccines are tailored to individual patients, training T cells to recognize and attack their tumors. The initiative could bring researchers, drugmakers, funding and clinical-trial networks together to advance promising approaches. Why Moderna? ?Its mRNA technology is central to its oncology ambitions. Its experimental melanoma vaccine with $MRK has already shown promising Phase 3 results. $MRNA’s Nasdaq-100 reentry also adds buying demand. The NIH initiative, however, is a research push—not guaranteed revenue.
0 replies
ryank3030 Oct 9, 8:36 PM
$EXPE closed out this morning at $270.13, +3.83% in 3 days 🎯 Bought Monday after the close at $260.17 and sold in the first few minutes of the open today. Nothing fancy: a pullback, a plan, and out when it hit. That's 3 for 3 on the swing book this week ($JNJ +2.5%, $MRK +2.5%, $EXPE +3.8%). Every trade, wins and losses, is logged publicly at https://bit.ly/4AXO1sx
0 replies
AmazingStockBuyer Oct 9, 6:33 PM
$PDSB $MRK is a good company
0 replies